Home >> Pharmaceuticals >> Food & Beverage >>

Global Psoriasis Therapeutics Market 2015-2019

Published: Dec-2014 | Format: PDF | Technavio | Number of pages: 109 | Code: MRS - 2905

Psoriasis is a common immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes buildup of thick white, red, or silvery patches of skin. It alters the normal cell cycle of the skin. The new cells of the skin grow and move quickly to the surface of the skin to form patches known as "plaques". The plaques are commonly found on knees, elbows, scalp, hands, and feet. Psoriasis occurs mostly in adults, but can also be seen in children and adolescents. The etiology of the disease is unknown, however, it is believed to be an immune-mediated process. It is believed that the over-activity of the immune system can cause inflammation, thereby resulting in flaking of the skin.

TechNavio's analysts forecast the Global Psoriasis Therapeutics market to grow at a CAGR of 9.95 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Psoriasis Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs including systemic and topical drugs used in the treatment of:

  • Psoriasis
  • Psoriatic Arthritis

The Global Psoriasis Therapeutics market is segmented based on the mechanism of action of the drugs used to treat psoriasis and psoriatic arthritis as illustrated below:

  • TNF Inhibitors
  • PDE4 Inhibitors
  • Interleukin Blockers
  • Others

The Global Psoriasis Therapeutics market is also segmented based on the type of molecule used for the treatment of psoriasis, as illustrated below:

  • Biologics
  • Small Molecules

On the basis of route of administration adopted for the treatment of psoriasis, the Global Psoriasis Therapeutics market is segmented as follows:

  • Oral
  • Parenteral
  • Topical

The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Psoriasis Therapeutics market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of psoriasis have been discussed.

TechNavio's report, Global Psoriasis Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and the EMEA regions; it also covers the Global Psoriasis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Pfizer

Other Prominent Vendors

  • AbGenomics
  • Almirall
  • Anacor Pharmaceuticals
  • ApoPharma
  • Astellas Pharma
  • AstraZeneca
  • Aurinia Pharmaceuticals
  • Biocon
  • Biogen Idec
  • Biotest
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Celgene
  • Coherus Biosciences
  • Creabilis
  • Dermira
  • Eli Lilly
  • F. Hofffmann-La Roche
  • Forward Pharma
  • G & W Laboratories
  • GlaxoSmithKline
  • Idera Pharmaceuticals
  • Kadmon
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Maruho
  • Merck
  • Moleculin
  • MorphoSys
  • Novartis
  • Pfizer
  • Promius Pharma
  • Provectus Biopharmaceuticals
  • Sandoz
  • Sun Pharmaceuticals
  • Takeda Pharmaceutical
  • Taro Pharmaceuticals
  • Therapeutics Inc.
  • UCB
  • Valeant Pharmaceuticals
  • VBL Therapeutics

Market Driver

  • Growing Unmet Needs
  • For a full, detailed list, view our report

Market Challenge

  • Unknown Disease Etiology
  • For a full, detailed list, view our report

Market Trend

  • Market Dominance by Biologics
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

1. Executive Summary

2. List of Abbreviations

3. Scope of the Report
3.1 Market Overview
3.2 Product Offerings

4. Product Profiles
4.1.1 Humira
4.1.2 Enbrel
4.1.3 Otezla
4.1.4 Remicade
4.1.5 Stelara

5. Market Research Methodology
5.1 Market Research Process
5.2 Research Methodology

6. Introduction

7. Market Landscape
7.1 Market Overview
7.2 Market Size and Forecast
7.3 Five Forces Analysis

8. Market Segmentation by Mechanism of Action
8.1 TNF Inhibitors
8.2 PDE4 Inhibitors
8.3 Interleukin Blockers
8.4 Others

9. Market Segmentation by Type of Molecule
9.1 Biologics
9.2 Small Molecules

10. Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
10.3 Topical

11. Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
11.3 Semi-solid

12. Market Segmentation by Type of Disease
12.1 Mild Psoriasis
12.2 Moderate Psoriasis
12.3 Severe Psoriasis

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Pipeline Portfolio

22. Novel Mechanisms Targeted by Pipeline Candidates
22.1 Small Molecules
22.1.1 Tofacitinib
22.1.2 Baricitinib
22.2 Biologics
22.2.1 Ixekizumab
22.2.2 Secukinumab
22.2.3 Brodalumab
22.2.4 Tildrakizumab
22.2.5 Guselkumab

23. Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2014
23.2.1 Competitive Assessment of Top Drugs for Psoriasis
23.2.2 Abbvie
23.2.3 Janssen Pharmaceuticals
23.2.4 Amgen
23.2.5 Pfizer
23.3 Other and Future Prominent Vendors

24. Key Vendor Analysis
24.1 Abbvie
24.1.1 Key Facts
24.1.2 Business Description
24.1.3 Business Segmentation
24.1.4 Revenue by Business Segmentation
24.1.5 Revenue Comparison 2013 and 2014
24.1.6 Sales by Geography
24.1.7 Business Strategy
24.1.8 Key Developments
24.1.9 SWOT Analysis
20.2 Amgen
24.2.1 Key Facts
24.2.2 Business Description
24.2.3 Business Segmentation
24.2.4 Revenue by Business Segmentation
24.2.5 Revenue Comparison 2013 and 2014
24.2.6 Sales by Geography
24.2.7 Business Strategy
24.2.8 Key Developments
24.2.9 SWOT Analysis
24.3 Janssen Pharmaceuticals
24.3.1 Key Facts
24.3.2 Business Description
24.3.3 Business Segmentation
24.3.4 Revenue by Business Segmentation
24.3.5 Revenue Comparison 2013 and 2014
24.3.6 Sales by Geography
24.3.7 Business Strategy
24.3.8 Key Developments
24.3.9 SWOT Analysis
24.4 Pfizer
24.4.1 Key Facts
24.4.2 Business Description
24.4.3 Business Segmentation
24.4.4 Revenue by Business Segmentation
24.4.5 Revenue Comparison 2013 and 2014
24.4.6 Sales by Geography
24.4.7 Business Strategy
24.4.8 Key Developments
24.4.9 SWOT Analysis

25. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of the Global Psoriasis Therapeutics Market
Exhibit 3: Global Psoriasis Therapeutics Market 2014-2019 (US$ million)
Exhibit 4: Drivers and Challenges of Global Psoriasis Therapeutics Market
Exhibit 5: Global Psoriasis Therapeutics Market Segmentation by Mechanism of Action
Exhibit 6: Global Psoriasis Therapeutics Market Segmentation by Mechanism of Action 2014
Exhibit 7: Global Psoriasis Therapeutics Market Segmentation by Type of Molecule
Exhibit 8: Global Psoriasis Therapeutics Market Segmentation by Type of Molecule 2014
Exhibit 9: Global Psoriasis Therapeutics Market Segmentation by Route of Administration
Exhibit 10: Global Psoriasis Therapeutics Market Segmentation by Route of Administration 2014
Exhibit 11: Global Psoriasis Therapeutics Market Segmentation by Dosage Form
Exhibit 12: Global Psoriasis Therapeutics Market Segmentation by Route of Administration 2014
Exhibit 13: Global Psoriasis Therapeutics Market Segmentation by Type of Disease
Exhibit 14: Global Psoriasis Therapeutics Market Segmentation by Type of Disease 2014
Exhibit 15: Global Psoriasis Therapeutics Market by Geographical Segmentation 2014
Exhibit 16: Buying Criteria of the Global Psoriasis Therapeutics Market
Exhibit 17: Drivers and Their Impact on the Key Customer Category of the Global Psoriasis Therapeutics Market
Exhibit 18: Drivers and Their Geography-wise Impact on the Global Psoriasis Therapeutics Market
Exhibit 19: Phase III Pipeline Molecules for Psoriasis
Exhibit 20: Percentage Comparison of Pipeline Molecules for Psoriasis Treatment
Exhibit 21: Novel Targets of the Pipeline Candidates
Exhibit 22: Candidates Under Development: Tofacitinib
Exhibit 23: Candidates Under Development: Baricitinib
Exhibit 24: Candidates Under Development: Ixekizumab
Exhibit 25: Candidates Under Development: Sekukinumab
Exhibit 26: Candidates Under Development: Brodalumab
Exhibit 27: Candidates Under Development: Tildrakizumab
Exhibit 28: Candidates Under Development: Guselkumab
Exhibit 29: YoY Sales Comparison of Top Drugs for Psoriasis 2010-2013 (US$ million)
Exhibit 30: Revenue Share of the Top Drugs for Psoriasis 2011-2013
Exhibit 31: YoY Global Sales of Humira 2008-2013
Exhibit 32: YoY Global Sales of Remicade 2005-2013
Exhibit 33: YoY Global Sales of Stelara 2005-2013
Exhibit 34: YoY Sales of Enbrel (In US and Canada) 2005-2013
Exhibit 35: YoY Sales of Enbrel In US 2005-2013
Exhibit 36: YoY Sales of Enbrel In Canada 2005-2013
Exhibit 37: Region-wise Sales Comparison of Enbrel 2005-2013
Exhibit 38: YoY Sales of Enbrel (Outside US and Canada) 2009-2013
Exhibit 39: Abbvie: Business Segmentation 2014
Exhibit 40: Abbvie: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 41: Abbvie: Sales by Geography (in US$ million)
Exhibit 42: Amgen: Business Segmentation by Revenue 2013 and 2014
Exhibit 43: Amgen: Sales by Geography 2014 (Pharmaceuticals Division)
Exhibit 44: Amgen: Sales by Geography 2014 (Diagnostics Division)
Exhibit 45: Janssen: Business Segmentation by Revenue 2014
Exhibit 46: Janssen: Business Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 47: Janssen: Sales by Geography 2014
Exhibit 48: Pfizer: Business Segmentation
Exhibit 49: Pfizer: Revenue by Business Segmentation 2014
Exhibit 50: Pfizer: Revenue by Business Segmentation 2013 and 2014 (US$ million)
Exhibit 51: Pfizer: Revenue by Geographical Segmentation 2014

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3000 View Pricing